Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
Stopped early · Phase 1/Phase 2
Conditions studied: Multiple Myeloma
In brief
The primary objective for part 1 of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma. The primary objective for part 2 is to evaluate the antitumor activity of CEP-18770 in patients treated at the MTD.
Key facts
- Study ID
- NCT01023880
- Run by
- Cephalon
- People needed
- 62
- Starts
- 2010-01-01
- Expected to finish
- 2013-01-01
- Last updated by the study team
- 2016-04-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic- Scottsdale — Scottsdale, Arizona, United States
- University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
- Stanford Heme Group — Palo Alto, California, United States
- University of California, San Francisco — San Francisco, California, United States
- Washington Cancer Institute — Washington D.C., District of Columbia, United States
- Northwestern University Medical School — Chicago, Illinois, United States
- Henry Ford Health System Protocol Review Committee — Detroit, Michigan, United States
- Sparrow Regional Cancer Center — Lansing, Michigan, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- John Theurer Cancer Center — Hackensack, New Jersey, United States
- Duke University Medical Center — Durham, North Carolina, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.